Department of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China.
Int J Oncol. 2023 Apr;62(4). doi: 10.3892/ijo.2023.5503. Epub 2023 Mar 17.
Photodynamic therapy (PDT) is an effective and low‑invasive tumour therapy. However, it can induce tumour angiogenesis, which is a main factor leading to tumour recurrence and metastasis. Activin receptor‑like kinase‑1 (ALK1) is a key factor regulating angiogenesis. However, it remains unclear whether ALK1 plays an unusual role in low‑dose PDT‑induced tumour angiogenesis. In the present study, human umbilical vein endothelial cells (HUVECs) co‑cultured with breast cancer MDA‑MB‑231 cells (termed HU‑231 cells) were used to construct an experimental model of tumour angiogenesis induced by low‑dose PDT. The viability, and the proliferative, invasive, migratory, as well as the tube‑forming ability of the HU‑231 cells were evaluated following low‑dose PDT. In particular, ALK1 inhibitor and and an adenovirus against ALK1 were used to further verify the role of ALK1 in low‑dose PDT‑induced tumour angiogenesis. Moreover, the expression of ALK1, inhibitor of DNA binding 1 (ID1), Smad 1, p‑Smad1/5, AKT and PI3K were detected in order to verify the underlying mechanisms. The findings indicated that low‑dose PDT enhanced the proliferative ability of the HU‑231 cells and reinforced their migratory, invasive and tube formation capacity. However, these effects were reversed with the addition of an ALK1 inhibitor or by the knockdown of ALK1 using adenovirus. These results indicated that ALK1 was involved and played a critical role in tumour angiogenesis induced by low‑dose PDT. Furthermore, ALK1 was found to participate in PDT‑induced tumour angiogenesis by activating the Smad1/5‑ID1 pathway, as opposed to the PI3K/AKT pathway. On the whole, the present study, for the first time, to the best of our knowledge, demonstrates that ALK1 is involved in PDT‑induced tumour angiogenesis. The inhibition of ALK1 can suppress PDT‑induced tumour angiogenesis, which can enhance the effects of PDT and may thus provide a novel treatment strategy for PDT.
光动力疗法(PDT)是一种有效的、微创的肿瘤治疗方法。然而,它可以诱导肿瘤血管生成,这是导致肿瘤复发和转移的主要因素。激活素受体样激酶 1(ALK1)是调节血管生成的关键因素。然而,目前尚不清楚 ALK1 在低剂量 PDT 诱导的肿瘤血管生成中是否发挥异常作用。在本研究中,用人脐静脉内皮细胞(HUVEC)与乳腺癌 MDA-MB-231 细胞共培养(称为 HU-231 细胞)构建了低剂量 PDT 诱导的肿瘤血管生成实验模型。评估低剂量 PDT 后 HU-231 细胞的活力、增殖、侵袭、迁移以及管形成能力。特别是,使用 ALK1 抑制剂和针对 ALK1 的腺病毒进一步验证了 ALK1 在低剂量 PDT 诱导的肿瘤血管生成中的作用。此外,还检测了 ALK1、DNA 结合抑制因子 1(ID1)、Smad1、p-Smad1/5、AKT 和 PI3K 的表达,以验证潜在的机制。结果表明,低剂量 PDT 增强了 HU-231 细胞的增殖能力,并增强了其迁移、侵袭和管形成能力。然而,这些作用被 ALK1 抑制剂的加入或通过腺病毒敲低 ALK1 而逆转。这些结果表明,ALK1 参与并在低剂量 PDT 诱导的肿瘤血管生成中发挥关键作用。此外,发现 ALK1 通过激活 Smad1/5-ID1 通路而不是 PI3K/AKT 通路参与 PDT 诱导的肿瘤血管生成。总的来说,本研究首次在我们所知的范围内表明,ALK1 参与 PDT 诱导的肿瘤血管生成。ALK1 的抑制可以抑制 PDT 诱导的肿瘤血管生成,从而增强 PDT 的效果,因此为 PDT 提供了一种新的治疗策略。